View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 24, 2019

Cancer Research UK to fund three international research projects

Cancer Research UK is set to fund three new international research projects focused on better understanding microbiome in human bodies, chronic inflammation and nature of certain cancers.

Cancer Research UK is set to fund three new international research projects focused on better understanding the microbiome in human bodies, as well as chronic inflammation and the nature of certain cancers.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The five-year programmes, which are part of the cancer research charity’s Grand Challenge competition, will receive approximately £60m in total funding. The projects include scientists from across the world, including North America, the UK, Europe and Israel.

For one of the reearch projects, a team from the US, Canada, the UK, the Netherlands and Spain will build upon their initial microbiome research that the microorganisms could be associated with bowel cancer and their response to therapy.

Prior studies also linked the potential influence of various lifestyle factors, such as diet and obesity, on the microbiome to the development of bowel cancer.

“By bringing them together across borders, Grand Challenge is enabling these teams to think bigger and establish new and exciting collaborations.”

Meanwhile, researchers from the US, Canada, the UK and Israel will come together in the second project to explore the relation between chronic inflammation and cancer.

The team will explore the scope of treating inflamed and non-cancerous stromal cells present in immediate surroundings of the cancer cells, instead of directly targeting the tumours.

This is based on the recently obtained data that the surroundings cells could control cancer development.

Under the third programme, US, UK and Netherlands scientists will investigate why genetic faults only affect select tissues. The findings will be used to better prevent or treat cancer in these organs.

Cancer Research UK chief executive Michelle Mitchel added: “These teams have five years to try to answer these complex questions about a disease that affects so many people, and we look forward to crossing new frontiers in our understanding of cancer.”

Iain Foulkes, Cancer Research’s executive director of research and innovation, said: “Individually, these research teams are among the best in the world in their respective fields.

“By bringing them together across borders, Grand Challenge is enabling these teams to think bigger and establish new and exciting collaborations. The scale of the funding reflects the opportunity we see in harnessing their ability to understand and tackle cancer.”

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology